LENZ Therapeutics, Inc. (LENZ)
(Delayed Data from NSDQ)
$27.25 USD
+1.02 (3.89%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $27.24 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LENZ 27.25 +1.02(3.89%)
Will LENZ be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for LENZ based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for LENZ
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
Lenz Therapeutics initiated with bullish view at Raymond James, here's why
Achieve, INmune, Lenz gain on bullish initiations from Raymond James
Lenz Therapeutics initiated with bullish view at Raymond James
RTW Biotech half-year net asset value rises amid "challenging markets"